Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma
A. Keith Stewart(Princess Margaret Hospital), Jesús G. Berdeja(Tennessee Oncology), James Scott McClellan, Yuanyuan Xiao(Jinan University), Divya Samineni, Andrew G. Polson(Sunesis (United States)), Jacqueline McBride, Eric W. Humke(Stanford University), Vanitha Ramakrishnan, Seema Singhal(All India Institute of Medical Sciences), Kirsten Mundt(Unknown), Jochen Brumm(Roche (Switzerland)), Sikander Ailawadhi(Jacksonville College), Douglas D. Leipold(Genesys (United States)), Rubén Niesvizky(Cornell University), Quyen Shon-Nguyen, Kyu Hong, Ralph V. Boccia(Center for Cancer and Blood Disorders), Manish R. Patel(Sarah Cannon), Amrita Krishnan(City of Hope), Asher Chanan‐Khan(WinnMed)
Cited by 62
Related Papers
Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
|New England Journal of Medicine|2012|2k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
|Nature Biotechnology|2008|1.4k